Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Photodynamic Therapy for Photodamage, Actinic Keratosis, and Acne in the Cosmetic Practice.

Moy LS, Frost D, Moy S.

Facial Plast Surg Clin North Am. 2020 Feb;28(1):135-148. doi: 10.1016/j.fsc.2019.09.012. Review.

PMID:
31779937
2.

Beyond detoxification: Pleiotropic functions of multiple glutathione S-transferase isoforms protect mice against a toxic electrophile.

Behrens KA, Jania LA, Snouwaert JN, Nguyen M, Moy SS, Tikunov AP, Macdonald JM, Koller BH.

PLoS One. 2019 Nov 20;14(11):e0225449. doi: 10.1371/journal.pone.0225449. eCollection 2019.

3.

Cannabidiol attenuates seizures and EEG abnormalities in Angelman syndrome model mice.

Gu B, Zhu M, Glass MR, Rougié M, Nikolova VD, Moy SS, Carney PR, Philpot BD.

J Clin Invest. 2019 Dec 2;129(12):5462-5467. doi: 10.1172/JCI130419.

4.

Modulation of CA2 neuronal activity increases behavioral responses to fear conditioning in female mice.

Alexander GM, Riddick NV, McCann KE, Lustberg D, Moy SS, Dudek SM.

Neurobiol Learn Mem. 2019 Sep;163:107044. doi: 10.1016/j.nlm.2019.107044. Epub 2019 Jul 15.

5.

Noradrenergic dysfunction accelerates LPS-elicited inflammation-related ascending sequential neurodegeneration and deficits in non-motor/motor functions.

Song S, Wang Q, Jiang L, Oyarzabal E, Riddick NV, Wilson B, Moy SS, Shih YI, Hong JS.

Brain Behav Immun. 2019 Oct;81:374-387. doi: 10.1016/j.bbi.2019.06.034. Epub 2019 Jun 24.

PMID:
31247288
6.

Prosocial effects of an oxytocin metabolite, but not synthetic oxytocin receptor agonists, in a mouse model of autism.

Moy SS, Teng BL, Nikolova VD, Riddick NV, Simpson CD, Van Deusen A, Janzen WP, Sassano MF, Pedersen CA, Jarstfer MB.

Neuropharmacology. 2019 Jan;144:301-311. doi: 10.1016/j.neuropharm.2018.10.036. Epub 2018 Nov 3.

PMID:
30399367
7.

A Mutation in the Borcs7 Subunit of the Lysosome Regulatory BORC Complex Results in Motor Deficits and Dystrophic Axonopathy in Mice.

Snouwaert JN, Church RJ, Jania L, Nguyen M, Wheeler ML, Saintsing A, Mieczkowski P, Manuel de Villena FP, Armao D, Moy SS, Lorenzo DN, Koller BH.

Cell Rep. 2018 Jul 31;24(5):1254-1265. doi: 10.1016/j.celrep.2018.06.118.

8.

Inter-α-inhibitor deficiency in the mouse is associated with alterations in anxiety-like behavior, exploration and social approach.

Goulding DR, Nikolova VD, Mishra L, Zhuo L, Kimata K, McBride SJ, Moy SS, Harry GJ, Garantziotis S.

Genes Brain Behav. 2019 Jan;18(1):e12505. doi: 10.1111/gbb.12505. Epub 2018 Aug 6.

9.

Mammalian TRIM67 Functions in Brain Development and Behavior.

Boyer NP, Monkiewicz C, Menon S, Moy SS, Gupton SL.

eNeuro. 2018 Jun 14;5(3). pii: ENEURO.0186-18.2018. doi: 10.1523/ENEURO.0186-18.2018. eCollection 2018 May-Jun. Erratum in: eNeuro. 2019 Aug 16;6(4):.

10.

The Temporal Dynamics of Arc Expression Regulate Cognitive Flexibility.

Wall MJ, Collins DR, Chery SL, Allen ZD, Pastuzyn ED, George AJ, Nikolova VD, Moy SS, Philpot BD, Shepherd JD, Müller J, Ehlers MD, Mabb AM, Corrêa SAL.

Neuron. 2018 Jun 27;98(6):1124-1132.e7. doi: 10.1016/j.neuron.2018.05.012. Epub 2018 May 31.

11.

Amelioration of Muscle and Nerve Pathology in LAMA2 Muscular Dystrophy by AAV9-Mini-Agrin.

Qiao C, Dai Y, Nikolova VD, Jin Q, Li J, Xiao B, Li J, Moy SS, Xiao X.

Mol Ther Methods Clin Dev. 2018 Jan 31;9:47-56. doi: 10.1016/j.omtm.2018.01.005. eCollection 2018 Jun 15.

12.

Effect of Environmental Enrichment on Aggression in BALB/cJ and BALB/cByJ Mice Monitored by Using an Automated System.

Giles JM, Whitaker JW, Moy SS, Fletcher CA.

J Am Assoc Lab Anim Sci. 2018 Apr 18. doi: 10.30802/AALAS-JAALAS-17-000122. [Epub ahead of print]

13.

Enhanced Operant Extinction and Prefrontal Excitability in a Mouse Model of Angelman Syndrome.

Sidorov MS, Judson MC, Kim H, Rougie M, Ferrer AI, Nikolova VD, Riddick NV, Moy SS, Philpot BD.

J Neurosci. 2018 Mar 14;38(11):2671-2682. doi: 10.1523/JNEUROSCI.2828-17.2018. Epub 2018 Feb 5.

14.

Common Pathophysiology in Multiple Mouse Models of Pitt-Hopkins Syndrome.

Thaxton C, Kloth AD, Clark EP, Moy SS, Chitwood RA, Philpot BD.

J Neurosci. 2018 Jan 24;38(4):918-936. doi: 10.1523/JNEUROSCI.1305-17.2017. Epub 2017 Dec 8.

15.

The enduring impact of neurulation stage alcohol exposure: A combined behavioral and structural neuroimaging study in adult male and female C57BL/6J mice.

Fish EW, Wieczorek LA, Rumple A, Suttie M, Moy SS, Hammond P, Parnell SE.

Behav Brain Res. 2018 Feb 15;338:173-184. doi: 10.1016/j.bbr.2017.10.020. Epub 2017 Oct 28.

16.

AR2, a novel automatic muscle artifact reduction software method for ictal EEG interpretation: Validation and comparison of performance with commercially available software.

Weiss SA, Asadi-Pooya AA, Vangala S, Moy S, Wyeth DH, Orosz I, Gibbs M, Schrader L, Lerner J, Cheng CK, Chang E, Rajaraman R, Keselman I, Churchman P, Bower-Baca C, Numis AL, Ho MG, Rao L, Bhat A, Suski J, Asadollahi M, Ambrose T, Fernandez A, Nei M, Skidmore C, Mintzer S, Eliashiv DS, Mathern GW, Nuwer MR, Sperling M, Engel J Jr, Stern JM.

Version 2. F1000Res. 2017 Jan 10 [revised 2017 Jan 1];6:30. doi: 10.12688/f1000research.10569.2. eCollection 2017.

17.

Hip region muscular dystrophy and emergence of motor deficits in dysferlin-deficient Bla/J mice.

Nagy N, Nonneman RJ, Llanga T, Dial CF, Riddick NV, Hampton T, Moy SS, Lehtimäki KK, Ahtoniemi T, Puoliväli J, Windish H, Albrecht D, Richard I, Hirsch ML.

Physiol Rep. 2017 Mar;5(6). pii: e13173. doi: 10.14814/phy2.13173.

18.
19.

An NLRP3 Mutation Causes Arthropathy and Osteoporosis in Humanized Mice.

Snouwaert JN, Nguyen M, Repenning PW, Dye R, Livingston EW, Kovarova M, Moy SS, Brigman BE, Bateman TA, Ting JP, Koller BH.

Cell Rep. 2016 Dec 13;17(11):3077-3088. doi: 10.1016/j.celrep.2016.11.052.

20.

Pharmacokinetic drug interaction study between overactive bladder drugs mirabegron and tolterodine in Japanese healthy postmenopausal females.

Nomura Y, Iitsuka H, Toyoshima J, Kuroishi K, Hatta T, Kaibara A, Katashima M, Moy S, Sawamoto T.

Drug Metab Pharmacokinet. 2016 Dec;31(6):411-416. doi: 10.1016/j.dmpk.2016.08.002. Epub 2016 Aug 18.

PMID:
27829538
21.

Ripples on spikes show increased phase-amplitude coupling in mesial temporal lobe epilepsy seizure-onset zones.

Weiss SA, Orosz I, Salamon N, Moy S, Wei L, Van't Klooster MA, Knight RT, Harper RM, Bragin A, Fried I, Engel J Jr, Staba RJ.

Epilepsia. 2016 Nov;57(11):1916-1930. doi: 10.1111/epi.13572. Epub 2016 Oct 10.

22.

Effects of Enrichment and Litter Parity on Reproductive Performance and Behavior in BALB/c and 129/Sv Mice.

Whitaker JW, Moy SS, Pritchett-Corning KR, Fletcher CA.

J Am Assoc Lab Anim Sci. 2016;55(4):387-99.

23.

Bcl-xL Is Essential for the Survival and Function of Differentiated Neurons in the Cortex That Control Complex Behaviors.

Nakamura A, Swahari V, Plestant C, Smith I, McCoy E, Smith S, Moy SS, Anton ES, Deshmukh M.

J Neurosci. 2016 May 18;36(20):5448-61. doi: 10.1523/JNEUROSCI.4247-15.2016.

24.

Acute alcohol exposure during neurulation: Behavioral and brain structural consequences in adolescent C57BL/6J mice.

Fish EW, Holloway HT, Rumple A, Baker LK, Wieczorek LA, Moy SS, Paniagua B, Parnell SE.

Behav Brain Res. 2016 Sep 15;311:70-80. doi: 10.1016/j.bbr.2016.05.004. Epub 2016 May 13.

25.

Trim9 Deletion Alters the Morphogenesis of Developing and Adult-Born Hippocampal Neurons and Impairs Spatial Learning and Memory.

Winkle CC, Olsen RH, Kim H, Moy SS, Song J, Gupton SL.

J Neurosci. 2016 May 4;36(18):4940-58. doi: 10.1523/JNEUROSCI.3876-15.2016.

26.

Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.

Sharma R, Park TE, Moy S.

Clin Ther. 2016 Mar;38(3):431-44. doi: 10.1016/j.clinthera.2016.01.018. Epub 2016 Mar 2. Review.

PMID:
26948862
27.

Making It Work Without a Family Drug Court: Connecticut's Approach to Parental Substance Abuse in the Child Welfare System.

Ungemack J, Giovannucci M, Moy S, Ohrenberger K, Dematteo T, Smith S.

Child Welfare. 2015;94(5):107-23.

PMID:
26827467
28.

Reversal of social deficits by subchronic oxytocin in two autism mouse models.

Teng BL, Nikolova VD, Riddick NV, Agster KL, Crowley JJ, Baker LK, Koller BH, Pedersen CA, Jarstfer MB, Moy SS.

Neuropharmacology. 2016 Jun;105:61-71. doi: 10.1016/j.neuropharm.2015.12.025. Epub 2015 Dec 31.

29.

Allosteric ligands for the pharmacologically dark receptors GPR68 and GPR65.

Huang XP, Karpiak J, Kroeze WK, Zhu H, Chen X, Moy SS, Saddoris KA, Nikolova VD, Farrell MS, Wang S, Mangano TJ, Deshpande DA, Jiang A, Penn RB, Jin J, Koller BH, Kenakin T, Shoichet BK, Roth BL.

Nature. 2015 Nov 26;527(7579):477-83. doi: 10.1038/nature15699. Epub 2015 Nov 9.

30.

Disruption of the microRNA 137 primary transcript results in early embryonic lethality in mice.

Crowley JJ, Collins AL, Lee RJ, Nonneman RJ, Farrell MS, Ancalade N, Mugford JW, Agster KL, Nikolova VD, Moy SS, Sullivan PF.

Biol Psychiatry. 2015 Jan 15;77(2):e5-7. doi: 10.1016/j.biopsych.2014.05.022. Epub 2014 Jun 11. No abstract available.

31.

Facilitation of serotonin signaling by SSRIs is attenuated by social isolation.

Dankoski EC, Agster KL, Fox ME, Moy SS, Wightman RM.

Neuropsychopharmacology. 2014 Dec;39(13):2928-37. doi: 10.1038/npp.2014.162. Epub 2014 Jul 1.

32.

Chemogenetic inactivation of ventral hippocampal glutamatergic neurons disrupts consolidation of contextual fear memory.

Zhu H, Pleil KE, Urban DJ, Moy SS, Kash TL, Roth BL.

Neuropsychopharmacology. 2014 Jul;39(8):1880-92. doi: 10.1038/npp.2014.35. Epub 2014 Feb 14.

33.

Response to the letter by Dubey et al. (2013).

Moy SS.

Neurotoxicol Teratol. 2014 Jan-Feb;41:97. doi: 10.1016/j.ntt.2013.10.006. Epub 2013 Nov 12. No abstract available.

PMID:
24231255
34.

Repetitive behavior profile and supersensitivity to amphetamine in the C58/J mouse model of autism.

Moy SS, Riddick NV, Nikolova VD, Teng BL, Agster KL, Nonneman RJ, Young NB, Baker LK, Nadler JJ, Bodfish JW.

Behav Brain Res. 2014 Feb 1;259:200-14. doi: 10.1016/j.bbr.2013.10.052. Epub 2013 Nov 8.

35.

Health outcomes of eating disorder clients in a rural setting.

Sheridan T, Brown LJ, Moy S, Harris D.

Aust J Rural Health. 2013 Aug;21(4):232-3. doi: 10.1111/ajr.12042. No abstract available.

PMID:
24033525
36.

Prosocial effects of oxytocin in two mouse models of autism spectrum disorders.

Teng BL, Nonneman RJ, Agster KL, Nikolova VD, Davis TT, Riddick NV, Baker LK, Pedersen CA, Jarstfer MB, Moy SS.

Neuropharmacology. 2013 Sep;72:187-96. doi: 10.1016/j.neuropharm.2013.04.038. Epub 2013 May 3.

37.

A case and care management program to reduce use of acute care by clients with substance use disorders.

Kirk TA, Di Leo P, Rehmer P, Moy S, Davidson L.

Psychiatr Serv. 2013 May 1;64(5):491-3. doi: 10.1176/appi.ps.201200258.

PMID:
23632578
38.

Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist.

Lee J, Moy S, Meijer J, Krauwinkel W, Sawamoto T, Kerbusch V, Kowalski D, Roy M, Marion A, Takusagawa S, van Gelderen M, Keirns J.

Clin Drug Investig. 2013 Jun;33(6):429-40. doi: 10.1007/s40261-013-0084-y.

PMID:
23625188
39.

Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults.

Lee J, Zhang W, Moy S, Kowalski D, Kerbusch V, van Gelderen M, Sawamoto T, Grunenberg N, Keirns J.

Clin Ther. 2013 Mar;35(3):333-41. doi: 10.1016/j.clinthera.2013.02.014.

PMID:
23497763
40.

A Gαs DREADD mouse for selective modulation of cAMP production in striatopallidal neurons.

Farrell MS, Pei Y, Wan Y, Yadav PN, Daigle TL, Urban DJ, Lee HM, Sciaky N, Simmons A, Nonneman RJ, Huang XP, Hufeisen SJ, Guettier JM, Moy SS, Wess J, Caron MG, Calakos N, Roth BL.

Neuropsychopharmacology. 2013 Apr;38(5):854-62. doi: 10.1038/npp.2012.251. Epub 2012 Dec 5.

41.

Behavioral deficits in an Angelman syndrome model: effects of genetic background and age.

Huang HS, Burns AJ, Nonneman RJ, Baker LK, Riddick NV, Nikolova VD, Riday TT, Yashiro K, Philpot BD, Moy SS.

Behav Brain Res. 2013 Apr 15;243:79-90. doi: 10.1016/j.bbr.2012.12.052. Epub 2013 Jan 4.

42.

Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.

Dickinson J, Lewand M, Sawamoto T, Krauwinkel W, Schaddelee M, Keirns J, Kerbusch V, Moy S, Meijer J, Kowalski D, Morton R, Lasseter K, Riff D, Kupčová V, van Gelderen M.

Clin Drug Investig. 2013 Jan;33(1):11-23. doi: 10.1007/s40261-012-0031-3.

PMID:
23208320
43.

Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study.

Malik M, van Gelderen EM, Lee JH, Kowalski DL, Yen M, Goldwater R, Mujais SK, Schaddelee MP, de Koning P, Kaibara A, Moy SS, Keirns JJ.

Clin Pharmacol Ther. 2012 Dec;92(6):696-706. doi: 10.1038/clpt.2012.181. Epub 2012 Nov 14.

PMID:
23149929
44.

Interleukin-6 (IL-6) receptor/IL-6 fusion protein (Hyper IL-6) effects on the neonatal mouse brain: possible role for IL-6 trans-signaling in brain development and functional neurobehavioral outcomes.

Brunssen SH, Moy SS, Toews AD, McPherson CA, Harry GJ.

Brain Behav Immun. 2013 Jan;27(1):42-53. doi: 10.1016/j.bbi.2012.08.017. Epub 2012 Sep 8.

45.

Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder.

Eltink C, Lee J, Schaddelee M, Zhang W, Kerbusch V, Meijer J, van Marle S, Grunenberg N, Kowalski D, Drogendijk T, Moy S, Iitsuka H, van Gelderen M, Matsushima H, Sawamoto T.

Int J Clin Pharmacol Ther. 2012 Nov;50(11):838-50. doi: 10.5414/CP201782.

PMID:
22943933
46.

Disruption of social approach by MK-801, amphetamine, and fluoxetine in adolescent C57BL/6J mice.

Moy SS, Nonneman RJ, Shafer GO, Nikolova VD, Riddick NV, Agster KL, Baker LK, Knapp DJ.

Neurotoxicol Teratol. 2013 Mar-Apr;36:36-46. doi: 10.1016/j.ntt.2012.07.007. Epub 2012 Aug 7.

47.

Preweaning sensorimotor deficits and adolescent hypersociability in Grin1 knockdown mice.

Moy SS, Nikolova VD, Riddick NV, Baker LK, Koller BH.

Dev Neurosci. 2012;34(2-3):159-73. Epub 2012 May 8.

48.

Effects of the selective kainate receptor antagonist ACET on altered sensorimotor gating in a genetic model of reduced NMDA receptor function.

Duncan GE, Koller BH, Moy SS.

Brain Res. 2012 Mar 14;1443:98-105. doi: 10.1016/j.brainres.2012.01.009. Epub 2012 Jan 20.

49.

Methodological lessons and pilot data on the effect of proximity of homes and schools to highways on pediatric asthma and lung function.

Brugge D, Hong JS, Schiff D, Hui C, Moy S, Palella M, Buchner V, Woodin M.

Rev Environ Health. 2011;26(2):119-25.

PMID:
21905455
50.

Variations in Maternal Behavior in C57BL/6J Mice: Behavioral Comparisons between Adult Offspring of High and Low Pup-Licking Mothers.

Pedersen CA, Vadlamudi S, Boccia ML, Moy SS.

Front Psychiatry. 2011 Jul 11;2:42. doi: 10.3389/fpsyt.2011.00042. eCollection 2011.

Supplemental Content

Support Center